1. Home
  2. CYTK vs CACI Comparison

CYTK vs CACI Comparison

Compare CYTK & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$78.68

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Logo CACI International Inc.

CACI

CACI International Inc.

HOLD

Current Price

$467.13

Market Cap

11.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
CACI
Founded
1997
1962
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
11.5B
IPO Year
2004
2007

Fundamental Metrics

Financial Performance
Metric
CYTK
CACI
Price
$78.68
$467.13
Analyst Decision
Strong Buy
Buy
Analyst Count
19
12
Target Price
$89.26
$689.50
AVG Volume (30 Days)
1.7M
229.1K
Earning Date
05-05-2026
04-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.00
EPS
N/A
17.11
Revenue
$13,368,000.00
$4,467,860,000.00
Revenue This Year
$7.37
$12.42
Revenue Next Year
$310.19
$10.00
P/E Ratio
N/A
$29.07
Revenue Growth
N/A
2.60
52 Week Low
$31.99
$445.48
52 Week High
$80.20
$683.50

Technical Indicators

Market Signals
Indicator
CYTK
CACI
Relative Strength Index (RSI) 62.37 29.38
Support Level $59.07 N/A
Resistance Level $79.66 $511.94
Average True Range (ATR) 3.20 19.94
MACD 0.51 -4.35
Stochastic Oscillator 83.65 7.61

Price Performance

Historical Comparison
CYTK
CACI

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

Share on Social Networks: